Literature DB >> 3943899

Isolation, purification, and partial characterization of a lipopolysaccharide from Haemophilus pleuropneumoniae.

J R Maudsley, S Kadis, W R Mayberry.   

Abstract

Lipopolysaccharide (LPS) from Haemophilus pleuropneumoniae 1536, serotype 2, was isolated and purified by a procedure designed to be equally satisfactory for both smooth- and rough-type LPS. The LPS yield was 53%. Analysis of the preparations revealed that protein, nucleic acid, and cellular phospholipid contamination was negligible (less than 0.1%). Analysis of the sugar content of the LPS by gas-liquid chromatography and colorimetric analysis revealed the presence of rhamnose, mannose, galactose, glucose, heptose, glucosamine, galactosamine, and 3-deoxy-D-manno-2-octulosonic acid. The heptose and glucose contents appeared to be unusually high. The fatty acids of the LPS consisted of a mixture of C14:0 and C16:0 in a ratio of about 4.5:1 (50% of the total) and 3-hydroxy C14:0. When used as a preparatory dose for the dermal Shwartzman reaction, as little as 10 micrograms of the LPS injected intradermally in rabbits produced reddening and swelling. After intravenous injection of a 100-micrograms LPS provoking dose, necrosis was observed at all intradermal injection sites. Limulus amebocyte lysate gelation was observed with an LPS concentration as low as 0.5 ng/ml. A typical biphasic fever response was noted in rabbits injected with as little as 0.25 ng of LPS per kg of body weight.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3943899      PMCID: PMC262364          DOI: 10.1128/iai.51.2.501-506.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

2.  Procedure for determining heptose and hexose in lipopolysaccharides. Modification of the cysteine-sulfuric acid method.

Authors:  B G Wright; P A Rebers
Journal:  Anal Biochem       Date:  1972-10       Impact factor: 3.365

3.  Interference by oxidized lipids in the determination of protein by the Lowry procedure.

Authors:  J Eichberg; L C Mokrasch
Journal:  Anal Biochem       Date:  1969-09       Impact factor: 3.365

4.  Interference of hexosamines in the Lowry reaction.

Authors:  J K Herd
Journal:  Anal Biochem       Date:  1971-12       Impact factor: 3.365

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Heterogeneity of antigenic-side-chain length in lipopolysaccharide from Escherichia coli 0111 and Salmonella typhimurium LT2.

Authors:  R C Goldman; L Leive
Journal:  Eur J Biochem       Date:  1980

7.  A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria.

Authors:  Y D Karkhanis; J Y Zeltner; J J Jackson; D J Carlo
Journal:  Anal Biochem       Date:  1978-04       Impact factor: 3.365

8.  Characterization of lipopolysaccharide of Haemophilus influenzae.

Authors:  A R Flesher; R A Insel
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

9.  Chemical composition and biological activities of a phenol-water extract from Haemophilus influenzae type a.

Authors:  D Raichvarg; C Brossard; J Agneray
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

10.  Studies of lipopolysaccharides from Pseudomonas aeruginosa.

Authors:  S G Wilkinson; L Galbrath
Journal:  Eur J Biochem       Date:  1975-03-17
View more
  10 in total

1.  Inhibition of bactericidal activity of anticapsular antibody by nonspecific antibodies reactive with surface-exposed antigenic determinants on Actinobacillus pleuropneumoniae.

Authors:  F A Udeze; S Kadis
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

2.  Identification of the heat-labile hemolysin of Actinobacillus pleuropneumoniae serotype 1.

Authors:  J Devenish; S Rosendal
Journal:  Can J Vet Res       Date:  1989-04       Impact factor: 1.310

3.  Actinobacillus pleuropneumoniae serotype 5, subtypes a and b: cross protection experiments.

Authors:  R Nielsen
Journal:  Acta Vet Scand       Date:  1988       Impact factor: 1.695

4.  Immunoserological comparison of 104-kilodalton proteins associated with hemolysis and cytolysis in Actinobacillus pleuropneumoniae, Actinobacillus suis, Pasteurella haemolytica, and Escherichia coli.

Authors:  J Devenish; S Rosendal; R Johnson; S Hubler
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

5.  A comparison of the potency of several Brucella allergens used to detect brucellosis in cattle.

Authors:  Z Bercovich; T Dekker; A Eger; J Haagsma
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

6.  Preparation, characterization, and immunogenicity of conjugate vaccines directed against Actinobacillus pleuropneumoniae virulence determinants.

Authors:  W Byrd; S Kadis
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

7.  Humoral antibody response and protective immunity in swine following immunization with the 104-kilodalton hemolysin of Actinobacillus pleuropneumoniae.

Authors:  J Devenish; S Rosendal; J T Bossé
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

8.  Molecular cloning and characterization of a hemolysin gene from Actinobacillus (Haemophilus) pleuropneumoniae.

Authors:  C J Lian; S Rosendal; J I MacInnes
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

9.  Structures and sugar compositions of lipopolysaccharides isolated from seven Actinobacillus pleuropneumoniae serotypes.

Authors:  W Byrd; S Kadis
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

10.  Antibody response of swine to outer membrane components of Haemophilus pleuropneumoniae during infection.

Authors:  V J Rapp; R F Ross
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.